NorthStrive Biosciences expands AI drug discovery with Yuva Biosciences
A six-month expansion program with Yuva Biosciences will narrow four validated AI-discovered compounds toward a nominated lead and designated backup. An amendment strengthens the exclusive cardiac disease and obesity field of use.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.